SCHEMBL16305750

SCHEMBL16305750

CCCCCCCOc1ccc(-c2cnc(-c3ccc(C[C@H](NC(=O)c4ccc(C(C)(C)CC)cc4)C(=O)N4CC[C@H](C(=O)O)C4)cc3)nc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ S1PR5 Q9H228 8/20 0.45
▸ HRH2 P25021 3/20 0.42
▸ HRH1 P35367 3/20 0.42
▸ HRH3 Q9Y5N1 7/20 0.40
▸ S1PR1 P21453 3/20 0.40
▸ S1PR3 Q99500 2/20 0.40
▸ PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16305691 0.94 S1PR5 (0.46) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16306019 0.94 S1PR5 (0.46) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL17834591 0.94 S1PR1 (0.44) S1PR5HRH2HRH1HRH3S1PR1
SCHEMBL17834831 0.93 S1PR5 (0.49) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16305732 0.92 S1PR5 (0.48) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16306062 0.92 S1PR5 (0.48) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16305731 0.92 S1PR5 (0.47) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16305728 0.92 S1PR5 (0.47) S1PR5HRH2HRH1HRH3S1PR1
SCHEMBL16380249 0.92 S1PR5 (0.47) S1PR5HRH2HRH1S1PR1S1PR3
SCHEMBL16306006 0.92 S1PR5 (0.47) S1PR5HRH2HRH1S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR5 889/4885HRH2 530/4885HRH1 485/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR5 889/4885HRH2 530/4885HRH1 485/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR5 889/4885HRH2 530/4885HRH1 485/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR5 889/4885HRH2 530/4885HRH1 485/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR S1PR5 939/4885HRH2 469/4885HRH1 426/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR S1PR5 939/4885HRH2 469/4885HRH1 426/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR5 889/4885HRH2 530/4885HRH1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback